Combined resistance training and high-protein diet to help frailty in sarcopenic obesity women

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Sixty obese elderly women with sarcopenia will be randomly assigned to two groups for 12 weeks. Group A will do supervised resistance training three times weekly plus a high-protein diet (1.3 g protein/kg/day) with meals evenly distributed and dietary tracking. Group B will receive a high-protein diet and general health advice without structured exercise, and will be offered the intervention after the study. Outcomes will be assessed to see if the combined approach improves muscle strength, function, and body composition compared with diet alone.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\) Female gender 2) Age 60-70 years 3) BMI ≥ 30 kg/m2 4) Sarcopenic patients diagnosed by their physicians according to EWGSOP2 criteria (low muscle strength confirmed by handgrip strength or chair stand test, plus low muscle quantity confirmed by BIA or DXA), and SARC-F score \>3.

  5\) Ambulatory and able to participate in exercise. 6) Stable medical condition. 7) The patients didn't follow any type of diet before the treatment at least 4 weeks ago.

  8\) Patients didn't follow any exercise program before treatment at least 4 weeks ago.

Exclusion Criteria:

* 1\) Sever cardiovascular, pulmonary, renal, or hepatic disease. 2) Uncontrolled diabetes or hypertension. 3) Neurological or musculoskeletal disorders prohibiting exercise 4) Cancer or other terminal illness. 5) Current use of anti-inflammatory drugs or steroids. 6) Metal implants prohibiting BIA assessment. 7) Cognitive impairment impairing ability to consent or follow instructions. 8) Using drugs that would affect metabolism or balance. 9) Using assistive devices for walking.

Where it's running

• Fawkia hospital outpatient clinic
  El-Sheikh Zayed City, Egypt Recruiting

Study contacts

• Principal investigator: shaimaa elsayed, master — Physical Therapy for Cardiovascular/Respiratory Disorder and Geriatrics, Faculty of Physical Therapy, Cairo University
• Study coordinator: Shaimaa Elsayed, master
• Email: drshaimaaelsayed1210@gmail.com
• Phone: 01063923818

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mechanical ventilation strategy to protect the lungs in obese adults during laparoscopic or robotic surgery

  This trial tests whether a specific intraoperative PEEP approach that uses transpulmonary pressure to limit lung power can improve breathing after surgery for adults with BMI 35 or higher undergoing laparoscopic or robotic procedures.

  Recruiting The University of Texas Medical Branch, Galveston · Galveston, Texas · NCT07774065

• Myokines in metabolic and endocrine diseases linked to sarcopenia

  This study tests whether myokines can serve as biomarkers or drivers of sarcopenia and sarcopenic obesity in people with metabolic or endocrine diseases.

  Recruiting Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Woluwe-Saint-Pierre - Sint-Pieters-Woluwe · NCT07703683

• How obesity affects daily activities and physical abilities in older adults

  This study tests how excess weight in people over 65 impacts daily tasks and physical performance, comparing obese seniors to normal-weight peers.

  Recruiting Istituto Auxologico Italiano · Oggebbio · NCT07614464

• SA030 Injection in Adults with Overweight or Obesity (Phase 1)

  This first-in-human study tests a single dose of SA030 to see if it is safe and well tolerated in adults who are overweight or obese.

  Recruiting at 2 sites Phase 1 Suzhou Siran Biotechnology Co.,Ltd. · Brisbane, Queensland and 1 other locations · NCT07479862

• Weekly injections of GIP (NNC0480-0389) plus amylin (cagrilintide) to see stomach side effects in adults with overweight or obesity

  This trial tests whether adding a GIP injection (NNC0480-0389) to weekly cagrilintide changes stomach-related side effects in adults with overweight or obesity.

  Recruiting Phase 1 Novo Nordisk A/S · Harrow, Middlesex · NCT07411560

• MB-1 vs placebo for weight and metabolic health in adults who are overweight or obese

  A study will test MB-1 to see if it helps adults who are overweight or obese lose weight and improve metabolic health compared to a placebo.

  Recruiting Arrae · London, Ontario · NCT07363148

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.